MIRA Pharmaceuticals, Inc. (MIRA) Stock Analysis & Investment Frameworks
MIRA Pharmaceuticals, Inc. (MIRA) stock analysis on Invetso. Review MIRA Pharmaceuticals, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
MIRA Pharmaceuticals, Inc. Company Overview
- Exchange: NASDAQ Capital Market
- Sector: Healthcare
- Industry: Drug Manufacturers - General
- Country: US
MIRA Pharmaceuticals, Inc. Key Financial Metrics
- Market Cap: $23.84M
- Revenue: $N/A
- ROE: -106.96%
- ROIC: -115.18%
- Dividend Yield: N/A
About MIRA Pharmaceuticals, Inc.
MIRA Pharmaceuticals, Inc. operates as a biopharmaceutical enterprise currently in the clinical development phase. Its main objective involves the creation and market introduction of a novel synthetic tetrahydrocannabinol (THC) analog. This compound is undergoing investigation for its potential to address anxiety and the cognitive impairments frequently observed in adult patients suffering from early-stage dementia. The firm's lead candidate, MIRA1a, is a synthetic cannabinoid analog engineered to alleviate both anxiety and chronic pain through its interaction with cannabinoid type 1 and type 2 receptors. Originally established in 2020 as MIRA1a Therapeutics, Inc., MIRA Pharmaceuticals, Inc. maintains its headquarters in Baltimore, Maryland.
MIRA Pharmaceuticals, Inc. Investment Frameworks
Invetso analyzes MIRA Pharmaceuticals, Inc. (MIRA) across the following frameworks:
- MIRA Pharmaceuticals, Inc. 10Y Growth Potential
- MIRA Pharmaceuticals, Inc. Scenario Analysis
- MIRA Pharmaceuticals, Inc. Risks & Opportunities
- MIRA Pharmaceuticals, Inc. Economic Moat
- MIRA Pharmaceuticals, Inc. Business Model
- MIRA Pharmaceuticals, Inc. Management
- MIRA Pharmaceuticals, Inc. SWOT Analysis
- MIRA Pharmaceuticals, Inc. Porter's 5 Forces
- MIRA Pharmaceuticals, Inc. PESTLE Analysis
- MIRA Pharmaceuticals, Inc. ESG Analysis